On August 5, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the quarter ending June 30, 2024, along with business highlights. The company reported a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities. CRISPR Therapeutics is advancing its pipeline with over 35 authorized treatment centers for CASGEVY™, its gene-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia. The company also highlighted ongoing clinical trials for its next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 respectively, and for in vivo gene editing product candidates, CTX310™ and CTX320™, targeting cardiovascular disease. Additionally, a Phase 1 clinical trial is ongoing for CTX211™, a treatment for Type 1 Diabetes. The company's collaboration with Vertex Pharmaceuticals continues to progress, with...Show More

On August 5, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the quarter ending June 30, 2024, along with business highlights. The company reported a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities. CRISPR Therapeutics is advancing its pipeline with over 35 authorized treatment centers for CASGEVY™, its gene-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia. The company also highlighted ongoing clinical trials for its next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 respectively, and for in vivo gene editing product candidates, CTX310™ and CTX320™, targeting cardiovascular disease. Additionally, a Phase 1 clinical trial is ongoing for CTX211™, a treatment for Type 1 Diabetes. The company's collaboration with Vertex Pharmaceuticals continues to progress, with Vertex leading the global development and commercialization of CASGEVY. CRISPR Therapeutics also announced new executive appointments, including Dr. Naimish Patel as Chief Medical Officer. For the second quarter of 2024, the company reported a net loss of $126.4 million, compared to a net loss of $77.7 million for the same period in 2023. The increase in net loss was attributed to higher collaboration expenses and reduced collaboration revenue.